In this letter to the House Energy and Commerce Committee’s Chair and Ranking Member, MACPAC expresses support for H.R. 1781, legislation that would permit it to access certain data on Medicaid prescription drug rebates that are now statutorily available only to the U.S. Department of Health and Human Services, the U.S. Department of Veterans Affairs, the U.S. Government Accountability Office, and the Congressional Budget Office. The letter notes that access to actual rebate data (e.g., average manufacturer price and best price) would significantly enhance the Commission’s ability to analyze the financial impact of policies targeted toward certain types or classes of drugs and their effects on certain manufacturers, drugs, or groups of beneficiaries.